SLC5A2 and atrial fibrillation: Observational and real-world studies report an upward trend in glucose-lowering prescriptions, specifically SGLT-2 inhibitors combined with other anti-diabetic agents, among patients with AF; hypothesis-generating analyses indicate these agents may target the arrhythmic substrate itself, rather than solely influencing CV or metabolic risk factors [25].